A prospective randomised controlled trial assessing the efficacy of Pegatanib sodium (Macugen®) in the prevention of proliferative diabetic retinopathy

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN27864936

Enrollment

Registered

2010-04-29

Start date

2009-01-01

Completion date

Unknown

Last updated

2016-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Topic: Eye

Interventions

90 subjects with ETDRS 53 A - E will be enrolled into the study. Baseline examination will include of best-corrected visual acuity (BCVA), fundus examination, 7-field retina colours and fundus fluores

Eligibility

Inclusion criteria

Inclusion criteria: Not provided at time of registration

Exclusion criteria

Exclusion criteria: Not provided at time of registration

Design outcomes

Primary

Measure	Time frame
The proportion of eyes that progress to ETDRS = 61 following three injections of intravitreal Macugen®	—

Secondary

Measure	Time frame
1. The mean change in size of foveal avascular zone (FAZ) from baseline to end of 12 months and 24 months 2. The rate (timepoint) of development of neovascularisation 3. Rates of ocular and non-ocular adverse events 4. The visual outcome in the study eye will be compared to control eyes	—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026